CL King Reiterates Buy Rating on Boston Scientific (BSX)

Boston Scientific (BSX) PT Raised to $98 at RBC Capital

RBC Capital analyst Shagun Singh raised the price target on Boston Scientific (NYSE: BSX) to $98.00 (from $95.00) while maintaining a Outperform rating.

The analyst comments "BSX reported impressive Q3'24 results (+18% y/y organic or 1,120bps above end-markets, and 26% y/y EPS growth)... More

Boston Scientific (BSX) PT Raised to $98 at Wells Fargo

Wells Fargo analyst Lawrence Biegelsen raised the price target on Boston Scientific (NYSE: BSX) to $98.00 (from $87.00) while maintaining a Overweight rating.... More

Buy the dip in this MedTech stock says Citi

As per analysts at Citi Research in a note dated Wednesday, the recent decline in Boston Scientifics stock presents a strong buying opportunity.

Despite delivering an exceptionally strong quarter, Boston Scientific Corporation has seen its share price decline due to concerns over a clinical trial pause.

The company reported $4.21 billion in revenue for the third quarter, an 18.2% organic increase, surpassing market expectations.

Its earnings per share of $0.63 marked a 27% year-on-year rise, prompting the company to raise its full-year... More

Boston Scientific raises annual earnings forecast, shares rise

Investing.com -- Boston Scientific (NYSE: BSX) stock climbed over 1% in premarket trading Wednesday after the company raised its full-year earnings guidance, surpassing the consensus estimate.

For the third quarter, the biotech firm reported earnings per share (EPS) of $0.63, surpassing the analyst estimate of... More

Boston Scientific (BSX) Tops Q3 EPS by 4c; offers guidance

Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.63, $0.04 better than the analyst estimate of $0.59. Revenue for the quarter came in at $4.21 billion versus the consensus estimate of $4.04 billion.

GUIDANCE:

Boston Scientific sees Q4 2024 EPS of $0.64-$0.66, versus the consensus of... More

Boston Scientific (BSX) call put ratio 1.7 calls to 1 put into quarter results

Boston Scientific (NYSE: BSX) October 25 weekly call option implied volatility is at 71, November is at 35; compared to its 52-week range of 16 to 32 into the expected release of quarter results after the bell on October 23.

iRhythm shares soar after FDA clears Zio AT device updates

Investing.com -- Shares of iRhythm Technologies, Inc. (NASDAQ: IRTC) surged 10.6% in pre-market trading on Tuesday after the company said that it had secured U.S. Food and Drug Administration clearance for updates made to its Zio AT device. 

The clearance follows a 510(k) submission related to design modifications that had previously been filed under a "letter to file," ensuring the cardiac telemetry device remains available for use in the United States.

Truist Securities has raised their price... More

Boston Scientific (BSX) call put ratio 2 calls to 1 put into quarter results

Boston Scientific (NYSE: BSX) October 25 weekly 88 straddle priced for a move of 6% into the expected release of quarter results after the bell on October 23.